title: [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
abstract: Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE). To investigate clinical and laboratory features of SLE-associated episcleritis and scleritis, we now report 4 cases of inpatients who were diagnosed with episcleritis or scleritis secondary to SLE from September 2005 to July 2016 in the Department of Rheumatology and Immunology in Peking University People's Hospital. Demographic, clinical and laboratory characteristics were summarized together with the treatment regimen and the prognosis; the literature was reviewed. There were 3 female and 1 male patients. The average age was (49.0±23.8) years and the mean duration of SLE at the onset of episcleritis or scleritis was (2.1±1.4) years. In addition to the eye involvement, the patients had mucocutaneous manifestations, serositis, lupus nephritis and interstitial pneumonia simultaneously; in the past, 1 patient experienced arthritis, 2 presented Raynaud's phenomenon, and 2 had hematologic involvement. All the patients had antinuclear antibody (ANA) of high titer. The anti double-stranded DNA (ds-DNA) antibody titers were increased in 2 patients. Three patients had positive anti-nucleosome antibody (ANuA) while the other 1 patient did not test it. The complement levels were decreased in 3 patients. The systemic lupus erythematosus disease activity index (SLEDAI) scores were more than 4 points in all the patients (ranging from 7-16), suggesting active disease. Ocular symptoms included pain, redness of the eye and tears. Ophthalmic examinations revealed 3 cases of episcleritis and 1 case of scleritis. Among the 4 patients, 2 patients experienced ocular complications including decrease in vision and uveitis. All the patients were treated with systemic corticosteroids combined with hydroxycloroquine; 3 patients were treated with immunosuppressants (cyclophosphamide in 2 patients and leflunomide in 1 patient). All of the 4 patients received topical steroid and 1 patient received periocular injection of triamcinolone acetonide; 1 patient received topical nonsteroidal anti-inflammatory drug (NSAID).No recurrence of episcleritis or scleritis was observed during the follow-ups. As a conclusion, scleritis and episcleritis, although uncommon, may occur in patients with autoimmune rheumatic diseases including SLE. The occurrence of episcleritis and scleritis may suggest active disease of SLE. Ocular complications need to be aware of in the patients. Prompt diagnosis and treatment was associated with good visual outcomes in the follow-ups.
authors.affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Department of Ophtalmology,Peking University People's Hospital, Beijing 100044, China.
authors.forename: H
authors.initials: H
authors.lastname: Miao
authors.affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Y S
authors.initials: YS
authors.lastname: Zhou
authors.affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: X Y
authors.initials: XY
authors.lastname: Zhang
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000097:blood; D001168:Arthritis / Q000150:complications; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006402:Hematologic Diseases / Q000150:complications; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D017563:Lung Diseases, Interstitial / Q000150:complications; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy*; D008181:Lupus Nephritis / Q000150:complications; D008297:Male; D008875:Middle Aged; D010146:Pain; D011379:Prognosis; D011928:Raynaud Disease / Q000150:complications; D012008:Recurrence; D015423:Scleritis / Q000150:complications* / Q000188:drug therapy*; D012700:Serositis / Q000150:complications; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D014605:Uveitis / Q000209:etiology; D014786:Vision Disorders / Q000209:etiology
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000974:Antibodies, Antinuclear; D007555:Isoxazoles; D003520:Cyclophosphamide; D014222:Triamcinolone Acetonide; D000077339:Leflunomide